AR056327A1 - Compuestos de nucleosidos para el tratamiento de infecciones virales - Google Patents

Compuestos de nucleosidos para el tratamiento de infecciones virales

Info

Publication number
AR056327A1
AR056327A1 ARP060101650A ARP060101650A AR056327A1 AR 056327 A1 AR056327 A1 AR 056327A1 AR P060101650 A ARP060101650 A AR P060101650A AR P060101650 A ARP060101650 A AR P060101650A AR 056327 A1 AR056327 A1 AR 056327A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
hydrogen
group
compounds
Prior art date
Application number
ARP060101650A
Other languages
English (en)
Inventor
Christopher Don Roberts
Ronald Conrad Griffith
Natalia B Dyatkina
Marija Prhavc
Original Assignee
Genelabs Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genelabs Tech Inc filed Critical Genelabs Tech Inc
Publication of AR056327A1 publication Critical patent/AR056327A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals

Abstract

Se exponen compuestos y uso de estos compuestos para preparar medicamentos. Estos compuestos son utiles para tratar infecciones virales causadas por un virus de la familia Flaviviridae, tal como el virus de la hepatitis C. Reivindicacion 1: Un compuesto de la formula (1) caracterizado porque: Y es O o CH2; X se selecciona de halo y O-W2; cada W, W1 y W2 se selecciona del grupo que consiste de hidrogeno, alquilo C1-4, y un grupo prodroga farmacéuticamente aceptable, previsto que cuando X es -O-W2, uno de W, W1 y W2 sea alquilo C1-4; R3 se selecciona del grupo que consiste de hidrogeno, OH, acilo, alquilo C1-4, y alcoxi C1-4; T se selecciona del grupo que consiste de: a) -C:::C-R, en donde R se selecciona del grupo que consiste de: i) hidrogeno; ii) tri-alquilsililoC1-4, -C(O)NR1R2, alcoxialquilo, heteroarilo, heteroarilo sustituido, fenilo, y fenilo sustituido; en donde R1 y R2 se seleccionan independientemente del grupo que consiste de hidrogeno, alquilo, alquilo sustituido, amino, amino sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, heterocíclico y heterocíclico sustituido previsto que solo uno de R1 y R2 es amino o amino sustituido, y además en donde R1 y R2, junto con el átomo de nitrogeno pendiente de este, forman un heterocíclico o heterocíclico sustituido; y iii) -C(O)OR14 , en donde R14 es hidrogeno, alquilo o alquilo sustituido; b) -CH=CH-Q2, en donde Q2 se selecciona de hidrogeno o cis-alcoxi; c) -C(O)H; d) -CH=NNHR15, en donde R15 es hidrogeno o alquilo C1-4; e) -CH=N(OR15), en donde R15 es como se definio anteriormente; f) -CH(OR16)2, en donde R16 es alquilo C3-6; g) -B(OR15)2, en donde R15 es como se definio anteriormente; y h) -NO2; o sales farmacéuticamente aceptables o sales parciales de éstos; previsto que cuando R3 es hidrogeno, OH, o alcoxi C1-3, entonces X es halo o -OalquiloC1-4.
ARP060101650A 2005-04-25 2006-04-25 Compuestos de nucleosidos para el tratamiento de infecciones virales AR056327A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67473105P 2005-04-25 2005-04-25

Publications (1)

Publication Number Publication Date
AR056327A1 true AR056327A1 (es) 2007-10-03

Family

ID=36764686

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101650A AR056327A1 (es) 2005-04-25 2006-04-25 Compuestos de nucleosidos para el tratamiento de infecciones virales

Country Status (4)

Country Link
US (1) US7405204B2 (es)
AR (1) AR056327A1 (es)
TW (1) TW200720285A (es)
WO (1) WO2006116557A1 (es)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1294735A2 (en) 2000-05-26 2003-03-26 Novirio Pharmaceuticals Limited Methods and compositions for treating flaviviruses and pestiviruses
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
KR20050035194A (ko) 2002-06-28 2005-04-15 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료용 2'-ｃ-메틸-3'-ｏ-ｌ-발린에스테르 리보푸라노실 사이티딘
CN1849142A (zh) 2002-11-15 2006-10-18 埃迪尼克斯(开曼)有限公司 2′－支链核苷和黄病毒突变
EP1976382B1 (en) 2005-12-23 2013-04-24 IDENIX Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
GB0623493D0 (en) * 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US7951789B2 (en) * 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
JP2010515680A (ja) * 2007-01-05 2010-05-13 メルク・シャープ・エンド・ドーム・コーポレイション Ｒｎａ依存性ｒｎａウイルス感染症の治療用としてのヌクレオシドアリールホスホロアミデート
AU2012241173B2 (en) * 2007-03-30 2014-09-25 Gilead Pharmasset Llc Nucleoside Phosphoramidate Prodrugs
AU2014233579B2 (en) * 2007-03-30 2016-06-23 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CA2711384C (en) * 2008-01-18 2016-07-26 Institute Of Organic Chemistry And Biochemistry As Cr, V.V.I. Cytostatic 7-deazapurine nucleosides
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010015637A1 (en) * 2008-08-06 2010-02-11 Novartis Ag New antiviral modified nucleosides
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
SG172361A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Nucleoside analogs
AR074897A1 (es) 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
CA3033133C (en) 2009-03-25 2021-11-09 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
WO2010114905A1 (en) * 2009-03-31 2010-10-07 Arqule, Inc. Peri-fused pyrazolo-pyrimidine compounds
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
PE20210668A1 (es) * 2009-09-21 2021-04-05 Gilead Sciences Inc Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales
SI2480559T1 (sl) 2009-09-21 2013-10-30 Gilead Sciences, Inc. Postopki in intermediati za pripravo 1'-ciano-karbanukleozidnih analogov
WO2011123672A1 (en) 2010-03-31 2011-10-06 Pharmasset, Inc. Purine nucleoside phosphoramidate
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
EP2752422B1 (en) 2010-03-31 2017-08-16 Gilead Pharmasset LLC Stereoselective synthesis of phosphorus containing actives
KR20200052384A (ko) 2010-07-19 2020-05-14 길리애드 사이언시즈, 인코포레이티드 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법
PT2595980E (pt) 2010-07-22 2014-11-27 Gilead Sciences Inc Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae
NZ607996A (en) 2010-09-22 2014-07-25 Alios Biopharma Inc Substituted nucleotide analogs
ES2716158T3 (es) 2010-11-30 2019-06-10 Gilead Pharmasset Llc 2'-spiro-nucleótidos para el tratamiento de hepatitis C
WO2012154321A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
AU2012242978A1 (en) 2011-04-13 2013-10-24 Merck Sharp & Dohme Corp. 2'-Cyano Substituted Nucleoside Derivatives and methods of use thereof for the treatment of viral diseases
JP2014515023A (ja) * 2011-04-13 2014-06-26 メルク・シャープ・アンド・ドーム・コーポレーション ２’−置換ヌクレオシド誘導体およびウイルス疾患の処置のためのその使用方法
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US9408863B2 (en) 2011-07-13 2016-08-09 Merck Sharp & Dohme Corp. 5′-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases
US9416154B2 (en) 2011-07-13 2016-08-16 Merck Sharp & Dohme Corp. 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
TW201329096A (zh) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
MD4589C1 (ro) 2011-09-16 2019-03-31 Gilead Pharmasset Llc Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
NZ702744A (en) * 2012-05-22 2016-12-23 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
UY34824A (es) 2012-05-25 2013-11-29 Janssen R & D Ireland Nucleósidos de espirooxetano de uracilo
US9192621B2 (en) 2012-09-27 2015-11-24 Idenix Pharmaceuticals Llc Esters and malonates of SATE prodrugs
EA030189B8 (ru) * 2012-10-08 2018-10-31 Иденикс Фармасьютикалз Ллс Аналоги 2'-хлоронуклеозидов для инфекции вгс
AR092959A1 (es) * 2012-10-17 2015-05-06 Merck Sharp & Dohme Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
NZ625087A (en) 2013-01-31 2017-05-26 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
WO2014135107A1 (zh) 2013-03-08 2014-09-12 南京圣和药业有限公司 新的核苷氨基磷酸酯化合物及其应用
EP2970357A1 (en) 2013-03-13 2016-01-20 IDENIX Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
ES2900570T3 (es) 2013-08-27 2022-03-17 Gilead Pharmasset Llc Formulación de combinación de dos compuestos antivirales
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
WO2016015638A1 (zh) * 2014-07-30 2016-02-04 南京圣和药业股份有限公司 丙型肝炎病毒抑制剂及其应用
US10286065B2 (en) 2014-09-19 2019-05-14 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
TWI698444B (zh) 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法
CN107771179A (zh) 2015-06-22 2018-03-06 桑多斯股份公司 氨基磷酸酯的合成
CA2998189C (en) 2015-09-16 2021-08-03 Gilead Sciences, Inc. Methods for treating arenaviridae and coronaviridae virus infections
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
US20190169221A1 (en) * 2016-08-12 2019-06-06 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN110869028B (zh) 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
CN115403626A (zh) 2017-05-01 2022-11-29 吉利德科学公司 新结晶形式
US10675296B2 (en) 2017-07-11 2020-06-09 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
WO2021154687A1 (en) 2020-01-27 2021-08-05 Gilead Sciences, Inc. Methods for treating sars cov-2 infections
CN115298181A (zh) 2020-03-12 2022-11-04 吉利德科学公司 制备1’-氰基核苷的方法
EP4132651A1 (en) 2020-04-06 2023-02-15 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CA3179226A1 (en) 2020-05-29 2021-12-02 Tomas Cihlar Remdesivir treatment methods
CN115996928A (zh) 2020-06-24 2023-04-21 吉利德科学公司 1’-氰基核苷类似物及其用途
CN114057814B (zh) * 2020-08-05 2023-12-08 广州市恒诺康医药科技有限公司 核苷类似物及其应用
PE20231983A1 (es) 2020-08-27 2023-12-12 Gilead Sciences Inc Compuestos y metodos para el tratamiento de infecciones virales
WO2023167944A1 (en) 2022-03-02 2023-09-07 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
AU7675491A (en) * 1990-04-04 1991-10-30 Chiron Corporation Hepatitis c virus protease
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DE69332105T2 (de) * 1992-09-29 2003-03-06 Inhale Therapeutic Systems San Pulmonale abgabe von aktiven fragmenten des parathormons
EP0693126B9 (en) * 1993-04-02 2007-09-12 Rigel Pharmaceuticals, Inc. Method for selective inactivation of viral replication
IT1272179B (it) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
US6150510A (en) * 1995-11-06 2000-11-21 Aventis Pharma Deutschland Gmbh Modified oligonucleotides, their preparation and their use
US5861267A (en) * 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
AU719122B2 (en) 1995-09-27 2000-05-04 Emory University Recombinant hepatitis C virus RNA replicase
US5759795A (en) * 1996-03-08 1998-06-02 Schering Corporation Assay for determining inhibitors of ATPase
KR20000075983A (ko) * 1997-03-05 2000-12-26 엘. 데이예를 카렌. 헤파타이티스 ｃ 바이러스 복제를 선택적으로 저해하는 물질을 확인하기 위한 새로운 스크리닝 방법
DE69838513T2 (de) * 1997-12-11 2008-07-03 Smithkline Beecham Corp. Verkürztes hepatitis-c-virus protein nsb5 und methoden, um antivirale substanzen zu identifizieren
RS50236B (sr) * 2001-01-22 2009-07-15 Merck & Co.Inc., Nukleozidni derivati kao inhibitori rnk-zavisne rnk virusne polimeraze
JP2005533108A (ja) 2002-07-16 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド Ｒｎａ依存性ｒｎａウイルスポリメラーゼの阻害剤としてのヌクレオシド誘導体
AU2003261434A1 (en) 2002-08-12 2004-02-25 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of hcv replication
US7094768B2 (en) * 2002-09-30 2006-08-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
NZ538457A (en) 2002-09-30 2008-04-30 Genelabs Tech Inc Nucleoside derivatives for treating hepatitis C virus infection
EP2345661A1 (en) 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
WO2005024268A1 (en) 2003-09-08 2005-03-17 Scott Ronald Thomas Line tensioning device and methods
US7144868B2 (en) * 2003-10-27 2006-12-05 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
AU2004295291A1 (en) * 2003-10-27 2005-06-16 Smithkline Beecham Corporation Nucleoside compounds for treating viral infections
CA2542776A1 (en) * 2003-10-27 2005-05-12 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US7169918B2 (en) * 2003-10-27 2007-01-30 Genelabs Technologies, Inc. Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives
US7202223B2 (en) * 2003-10-27 2007-04-10 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US7414031B2 (en) * 2004-11-22 2008-08-19 Genelabs Technologies, Inc. 5-nitro-nucleoside compounds for treating viral infections
EP1853617A1 (en) * 2005-02-28 2007-11-14 Genelabs Technologies, Inc. Tricyclic-nucleoside prodrugs for treating viral infections

Also Published As

Publication number Publication date
US20060241064A1 (en) 2006-10-26
WO2006116557A1 (en) 2006-11-02
US7405204B2 (en) 2008-07-29
TW200720285A (en) 2007-06-01

Similar Documents

Publication Publication Date Title
AR056327A1 (es) Compuestos de nucleosidos para el tratamiento de infecciones virales
RU2500680C2 (ru) Новые замещенные пиридин-2-оны и пиридазин-3-оны
AR057023A1 (es) Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa
ECSP055815A (es) Composición para el tratamiento de la infección por virus flaviviridae
AR052458A1 (es) Amino-imidazolonas para la inhibicion de beta-secretasa
AR085327A1 (es) Inhibidores del virus de la hepatitis c
EA200970478A1 (ru) Аналоги тиофена для лечения или предупреждения флавивирусных инфекций
NZ630259A (en) Heterobicyclic compounds as beta-lactamase inhibitors
AR067105A1 (es) Moleculas pequenas que contienen boro
EA200970493A1 (ru) Макроциклические ингибиторы вируса гепатита с
CO6231002A2 (es) Compuestos utiles como ligandos para tomar imagenes de inervacion cardiaca
HRP20120523T1 (hr) Inhibitori virusa hepatitisa c
AR053120A1 (es) Aminopiridinas como inhibidores de beta secretasa
PE20130375A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
EA200800476A1 (ru) Макроциклические ингибиторы вируса гепатита с
AR078157A1 (es) Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer
AR064319A1 (es) Compuestos y composiciones farmaceuticas derivadas de sulfonamida ciclicos, proceso de preparacion y usos en el tratamiento de trastornos vasomotrices, sexuales, gastrointestinales y otros
DE602004031258D1 (de) Polycyclische mittel zur behandlung von infektione
TW200635585A (en) Monocyclic substituted methanones
EA201000017A1 (ru) Предварительная композиция серного цемента и способ приготовления предварительной композиции серного цемента
ECSP077402A (es) Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica
AR080185A1 (es) Derivados de acido boronico y benzofurano, composiciones farmaceuticas que los contienen,y uso de los mismos en el tratamiento y/o prevencion de infecciones virales, en particular por el virus de hepatitis c(hcv).
RU2009146124A (ru) Дигидрохиноновые и дигидронафтиридиновые ингибиторы киназы jnk
CO6321159A2 (es) Compuestos pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias
PE20220252A1 (es) Compuestos de pirrol

Legal Events

Date Code Title Description
FA Abandonment or withdrawal